Facetten
Zugriff
Einrichtung
Medientyp
- Text 21
Karte
Erscheinungsjahr
Autor/in
- Goldschmidt, Hartmut
- Weisel, Katja 6
- Basu, Supratik 4
- Facon, Thierry 4
- Hulin, Cyrille 4
- alle zeigen
Sprache
21 Einträge gefunden
-
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
- Facon, Thierry
- Kumar, Shaji K
- Plesner, Torben
- Orlowski, Robert Z
- Moreau, Philippe
- Bahlis, Nizar
- Basu, Supratik
-
Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance
- Piechotta, Vanessa
- Skoetz, Nicole
- Engelhardt, Monika
- Einsele, Hermann
- Goldschmidt, Hartmut
- Scheid, Christof
-
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
- Facon, Thierry
- Cook, Gordon
- Usmani, Saad Z
- Hulin, Cyrille
- Kumar, Shaji
- Plesner, Torben
- Touzeau, Cyrille
-
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
- Dimopoulos, Meletios A
- Richardson, Paul G
- Bahlis, Nizar J
- Grosicki, Sebastian
- Cavo, Michele
- Beksaç, Meral
- Legieć, Wojciech
-
MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)
- Hillengass, Jens
- Cohen, Adam D
- Delforge, Michel
- Einsele, Hermann
- Goldschmidt, Hartmut
- Weisel, Katja
- Raab, Marc-Steffen
-
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
- Goldschmidt, Hartmut
- Mai, Elias K
- Bertsch, Uta
- Fenk, Roland
- Nievergall, Eva
- Tichy, Diana
- Besemer, Britta
-
MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma
- Stroh, Jacob
- Seckinger, Anja
- Heider, Michael
- Rudelius, Martina
- Eichner, Ruth
- Schick, Markus
- Slawska, Jolanta
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- Mateos, Maria-Victoria
- Weisel, Katja
- De Stefano, Valerio
- Goldschmidt, Hartmut
- Delforge, Michel
- Mohty, Mohamad
- Cavo, Michele
-
Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison
- Weisel, Katja
- Nooka, Ajay K
- Terpos, Evangelos
- Spencer, Andrew
- Goldschmidt, Hartmut
- Dirnberger, Franziska
- DeCosta, Lucy
-
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
- Goldschmidt, Hartmut
- Baertsch, Marc-Andrea
- Schlenzka, Jana
- Becker, Natalia
- Habermehl, Christina
- Hielscher, Thomas
- Raab, Marc-Steffen
-
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
- Facon, Thierry
- Kumar, Shaji K
- Plesner, Torben
- Orlowski, Robert Z
- Moreau, Philippe
- Bahlis, Nizar
- Basu, Supratik
-
-
-
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
- Raab, Marc S
- Engelhardt, Monika
- Blank, Antje
- Goldschmidt, Hartmut
- Agis, Hermine
- Blau, Igor W
- Einsele, Hermann
-
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
- Goldschmidt, Hartmut
- Dimopoulos, Meletios A
- Rajkumar, S Vincent
- Weisel, Katja C
- Moreau, Philippe
- Chng, Wee-Joo
- Mikala, Gábor
-
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials
- Weisel, Katja
- Majer, Istvan
- DeCosta, Lucy
- Oriol, Albert
- Goldschmidt, Hartmut
- Ludwig, Heinz
- Campioni, Marco
-
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
- Fenk, Roland
- Giagounidis, Aristoteles
- Goldschmidt, Hartmut
- Heinsch, Michael
- Rummel, Mathias
- Kroger, Nicolaus
- Boquoi, Amelie
-
-
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- Facon, Thierry
- Kumar, Shaji
- Plesner, Torben
- Orlowski, Robert Z
- Moreau, Philippe
- Bahlis, Nizar
- Basu, Supratik
-
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
- Garderet, Laurent
- Iacobelli, Simona
- Koster, Linda
- Goldschmidt, Hartmut
- Johansson, Jan-Erik
- Bourhis, Jean Henri
- Krejci, Marta